Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 3/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23867606 | 0.79 | PPM1D (0.43) | PPM1DEPHX1ALDH1A1PLAUL3MBTL1 | |
| SCHEMBL31277233 | 0.78 | NPC1 (0.56) | PPM1DEPHX1ALDH1A1PLAUTDP1 | |
| SCHEMBL9005566 | 0.74 | PPM1D (0.64) | PPM1DEPHX1PLAU | |
| SCHEMBL9005670 | 0.74 | PPM1D (0.64) | PPM1DEPHX1PLAU | |
| SCHEMBL28242711 | 0.73 | OPRM1 (0.59) | PPM1DEPHX1F2RL1PLAUGAA | |
| SCHEMBL6950371 | 0.73 | ERCC5 (0.51) | PPM1DPLAUNPC1 | |
| SCHEMBL1345174 | 0.69 | LTB4R (0.46) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL19245054 | 0.68 | L3MBTL1 (0.38) | ALDH1A1PLAUGAAL3MBTL1NPC1 | |
| SCHEMBL757429 | 0.67 | LOXL2 (0.62) | PPM1DALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL16191538 | 0.67 | EED (0.40) | EPHX1ALDH1A1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300972-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY, CLEAVABLE PORTION, AND REACTIVE GROUP, OR SALT THEREOF | AJINOMOTO CO., INC. (JP) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300972-A1 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY, CLEAVABLE PORTION, AND REACTIVE GROUP, OR SALT THEREOF | FCGR3B, FCGR2A, QPCTL | PPM1D 4818/4885EPHX1 3237/4885F2RL1 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.